Trial reportRheumatology (Oxford, England)2026
Subcutaneous versus intravenous ultra-low-dose rituximab in rheumatoid arthritis: a randomized controlled PK-PD non-inferiority trial.
Trial report in Rheumatology (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesUltra-low-dose rituximab is an effective treatment in RA. S.c. administration may further facilitate rituximab treatment, reduce infection risk and reduce costs. This study aimed to assess non-inferiority of s.c. vs i.v. rituximab regarding pharmacokinetic and pharmacodynamic outcomes.
methodsIn this randomized, open-label, non-inferiority study, RA patients with stable low disease activity on ultra-low-dose rituximab (500 mg or 200 mg every 6 months) were 1:1 randomized to receive rituximab 336 mg s.c. or 200 mg i.v., stratified by previous rituximab dose. Primary outcome was non-inferiority of s.c. to i.v. rituximab, based on the estimated rituximab serum concentration area under the curve during the first 6 months (AUC0-6m), with a non-inferiority margin of 0.8. AUCs were estimated using PK modelling. Secondary outcomes included change in DAS28-CRP compared with a non-inferiority margin of 0.6.
resultsThirty-five patients were randomized (17 i.v., 18 s.c.). The geometric mean ratio for AUC0-6m was 0.99 (90% CI 0.82-1.20), with minimal bias [mean predication error: i.v. 13.1 (1.86%); s.c. -3.40 (-0.47%)] but moderate random prediction error [root mean square error: i.v. 140 (19.8%); s.c. 142 (19.5%)] for the AUC estimates. Mean change in DAS28-CRP was non-inferior for s.c. rituximab (-0.39, 95% CI -0.77 to -0.004).
conclusionOur data suggest non-inferior pharmacokinetics for s.c. rituximab; however, this cannot be definitively concluded due to uncertainty of the AUC estimates. Nevertheless, based on pharmacokinetic and pharmacodynamic parameters, ultra-low-dose s.c. rituximab could be an alternative for ultra-low-dose i.v. rituximab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.